Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Eiseman

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|May 13, 1999
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and ratsM J Egorin, Z M Yuan, D L Sentz, et al.
Journal of Medicinal Chemistry|February 2, 1999
Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serumM J Kavarana, E G Kovaleva, D J Creighton, et al.
Journal of Medicinal Chemistry|May 29, 1999
A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxidesD S Hamilton, M J Kavarana, E M Sharkey, et al.
Antiviral Research|December 1, 1991
Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDSJ L Eiseman, R A Yetter, T N Fredrickson, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytesJ A Bilello, J J Kort, C MacAuley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpeneM J Egorin, D M Rosen, S E Benjamin, et al.
Cancer Research|June 11, 1998
Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparationsM J Egorin, D M Rosen, J H Wolff, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1M J Egorin, E G Zuhowski, D M Rosen, et al.
Cancer Chemotherapy and Pharmacology|August 14, 1999
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agentM J Egorin, E G Zuhowski, D L Sentz, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 miceJ L Eiseman, Z M Yuan, N D Eddington, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|May 13, 1999
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and ratsM J Egorin, Z M Yuan, D L Sentz, et al.
Journal of Medicinal Chemistry|February 2, 1999
Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serumM J Kavarana, E G Kovaleva, D J Creighton, et al.
Journal of Medicinal Chemistry|May 29, 1999
A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxidesD S Hamilton, M J Kavarana, E M Sharkey, et al.
Antiviral Research|December 1, 1991
Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDSJ L Eiseman, R A Yetter, T N Fredrickson, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytesJ A Bilello, J J Kort, C MacAuley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpeneM J Egorin, D M Rosen, S E Benjamin, et al.
Cancer Research|June 11, 1998
Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparationsM J Egorin, D M Rosen, J H Wolff, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1M J Egorin, E G Zuhowski, D M Rosen, et al.
Cancer Chemotherapy and Pharmacology|August 14, 1999
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agentM J Egorin, E G Zuhowski, D L Sentz, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 miceJ L Eiseman, Z M Yuan, N D Eddington, et al.
Pageof 4